

# Jennifer K Logue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6171147/publications.pdf>

Version: 2024-02-01

27  
papers

3,926  
citations

516710

16  
h-index

580821

25  
g-index

46  
all docs

46  
docs citations

46  
times ranked

7660  
citing authors

#	ARTICLE	IF	CITATIONS
1	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	27.8	917
2	Sequelae in Adults at 6 Months After COVID-19 Infection. <i>JAMA Network Open</i> , 2021, 4, e210830.	5.9	663
3	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. <i>Science</i> , 2020, 370, .	12.6	511
4	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	12.6	232
5	Cryptic transmission of SARS-CoV-2 in Washington state. <i>Science</i> , 2020, 370, 571-575.	12.6	217
6	Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 197-205.	4.0	216
7	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <i>Cell</i> , 2022, 185, 872-880.e3.	28.9	165
8	Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. <i>Cell</i> , 2022, 185, 1588-1601.e14.	28.9	137
9	Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection. <i>JAMA Network Open</i> , 2020, 3, e2016382.	5.9	104
10	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 0, , .	27.8	101
11	Early Detection of Covid-19 through a Citywide Pandemic Surveillance Platform. <i>New England Journal of Medicine</i> , 2020, 383, 185-187.	27.0	97
12	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	4.7	48
13	Epitope profiling reveals binding signatures of SARS-CoV-2 immune response in natural infection and cross-reactivity with endemic human CoVs. <i>Cell Reports</i> , 2021, 35, 109164.	6.4	44
14	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. <i>JCI Insight</i> , 2021, 6, .	5.0	39
15	High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. <i>Cell</i> , 2021, 184, 2927-2938.e11.	28.9	35
16	A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections. <i>Science Advances</i> , 2021, 7, eabj0274.	10.3	28
17	The Seattle Flu Study: a multiarm community-based prospective study protocol for assessing influenza prevalence, transmission and genomic epidemiology. <i>BMJ Open</i> , 2020, 10, e037295.	1.9	25
18	Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. <i>ELife</i> , 2022, 11, .	6.0	19

#	ARTICLE	IF	CITATIONS
19	Remote Household Observation for Noninfluenza Respiratory Viral Illness. <i>Clinical Infectious Diseases</i> , 2021, 73, e4411-e4418.	5.8	17
20	Dynamics of breast milk antibody titer in the six months following SARS-CoV-2 infection. <i>Journal of Clinical Virology</i> , 2021, 142, 104916.	3.1	15
21	SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma. <i>Microbiology Spectrum</i> , 2021, 9, e0129821.	3.0	15
22	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. <i>PLoS Pathogens</i> , 2022, 18, e1010592.	4.7	13
23	Cross-Sectional Prevalence of SARS-CoV-2 Among Skilled Nursing Facility Employees and Residents Across Facilities in Seattle. <i>Journal of General Internal Medicine</i> , 2020, 35, 3302-3307.	2.6	11
24	LB21. The Seattle Flu Study: A Community-Based Study of Influenza. <i>Open Forum Infectious Diseases</i> , 2019, 6, S1002-S1002.	0.9	8
25	Incidence of Medically Attended Acute Respiratory Illnesses Due to Respiratory Viruses Across the Life Course During the 2018/19 Influenza Season. <i>Clinical Infectious Diseases</i> , 2021, 73, 802-807.	5.8	8
26	Detailed analysis of antibody responses to SARS-CoV-2 vaccination and infection in macaques. <i>PLoS Pathogens</i> , 2022, 18, e1010155.	4.7	6
27	Challenges and lessons in establishing human immune profiling cohort studies for pandemic response. <i>Immunological Reviews</i> , 0, , .	6.0	1